GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (MIL:PHIL) » Definitions » PS Ratio

Philogen SpA (MIL:PHIL) PS Ratio : 328.95 (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Philogen SpA's share price is €18.75. Philogen SpA's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.06. Hence, Philogen SpA's PS Ratio for today is 328.95.

The historical rank and industry rank for Philogen SpA's PS Ratio or its related term are showing as below:

MIL:PHIL' s PS Ratio Range Over the Past 10 Years
Min: 23.8   Med: 37.31   Max: 328.95
Current: 327.2

During the past 4 years, Philogen SpA's highest PS Ratio was 328.95. The lowest was 23.80. And the median was 37.31.

MIL:PHIL's PS Ratio is ranked worse than
91.03% of 1015 companies
in the Biotechnology industry
Industry Median: 8.73 vs MIL:PHIL: 327.20

Philogen SpA's Revenue per Sharefor the six months ended in Jun. 2024 was €0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.06.

During the past 12 months, the average Revenue per Share Growth Rate of Philogen SpA was -91.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 63.70% per year.

During the past 4 years, Philogen SpA's highest 3-Year average Revenue per Share Growth Rate was 63.70% per year. The lowest was 63.70% per year. And the median was 63.70% per year.

Back to Basics: PS Ratio


Philogen SpA PS Ratio Historical Data

The historical data trend for Philogen SpA's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA PS Ratio Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PS Ratio
- 227.62 24.08 32.17

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PS Ratio Get a 7-Day Free Trial Premium Member Only - 24.08 - 32.17 -

Competitive Comparison of Philogen SpA's PS Ratio

For the Biotechnology subindustry, Philogen SpA's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Philogen SpA's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Philogen SpA's PS Ratio distribution charts can be found below:

* The bar in red indicates where Philogen SpA's PS Ratio falls into.



Philogen SpA PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Philogen SpA's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=18.75/0.057
=328.95

Philogen SpA's Share Price of today is €18.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Philogen SpA's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Philogen SpA  (MIL:PHIL) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Philogen SpA PS Ratio Related Terms

Thank you for viewing the detailed overview of Philogen SpA's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Philogen SpA Business Description

Traded in Other Exchanges
Address
Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Philogen SpA Headlines

From GuruFocus